Sino Biopharm CEO Eric Tse on Outlook, Asian Pharmaceutical Market & Trump

The transcript discusses the transition of the Chinese pharmaceutical market from generics to innovation, emphasizing globalization and market expansion. It highlights opportunities in the Pan Asia market and the challenges of conducting clinical trials. The speaker also addresses M&A activities, licensing agreements, and the impact of government reforms and tariffs on the industry.

What is the current focus of the Chinese pharmaceutical market according to the transcript?

• Expanding only within China

• Focusing solely on generics

• Transitioning from generics to innovation

• Maintaining a balance between generics and innovation

What story is used to illustrate the necessity of globalization?

• A story about TikTok refugees

• A story about pharmaceutical mergers

• A story about government reforms

• A story about supply chain challenges

Which market is identified as having significant potential for conducting clinical trials?

• South American market

• North American market

• Pan Asia market

• European market

What is the company's strategy for entering the global market?

• Gradually entering through Pan Asia and MENA markets

• Avoiding global markets altogether

• Focusing only on the American market

• Entering the global market in one step

What is the company's approach to mergers and acquisitions this year?

• Avoiding any new deals

• Continuing to look for opportunities

• Exiting the global market

• Focusing solely on internal operations

What has been the most important reform for the pharmaceutical industry according to the transcript?

• Reduction in generics production

• Focus on local markets

• Environment for innovation

• Increased tariffs

How do the Trump tariffs potentially impact the company?

• They significantly reduce revenue

• They have no impact on the supply chain

• They may increase challenges in the supply chain

• They lead to increased generics production